Vaccines have saved millions of lives, but delivering them safely remains a major logistical challenge. Most vaccines must be stored and transported within a narrow temperature range, usually between 2°C and 8°C, to maintain their effectiveness.

This system, known as the "cold chain," requires refrigerators, insulated transport and reliable electricity from the factory to the clinic. Now, scientists are testing a new vaccine technology that could eliminate this requirement altogether.

A thermostable vaccine designed to remain effective even at room temperature has shown promising results in an early human trial.

Researchers say the innovation could transform how vaccines are distributed, particularly in regions where maintaining refrigeration is difficult.

The vaccine, called SPVX02, targets tetanus and diphtheria and was developed by UK-based biotechnology company Stablepharma with support from the UK Health Security Agency.

Early results suggest the vaccine can remain stable at temperatures around 30°C for up to two years, raising the possibility of immunisation programmes that no longer depend on continuous refrigeration. 

Public health experts say such technology could significantly improve vaccine access in low- and middle-income countries, reduce wastage and simplify global immunisation efforts.

Source:Ndtv